{"id":"NCT02114151","sponsor":"Janssen Infectious Diseases BVBA","briefTitle":"Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis","officialTitle":"A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-04","primaryCompletion":"2015-01","completion":"2015-04","firstPosted":"2014-04-15","resultsPosted":"2016-04-04","lastUpdate":"2016-04-04"},"enrollment":103,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Virus Infection"],"interventions":[{"type":"DRUG","name":"Simeprevir","otherNames":[]},{"type":"DRUG","name":"Sofosbuvir","otherNames":[]}],"arms":[{"label":"Arm 1 (Simeprevir/Sofosbuvir)","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to investigate the efficacy and safety of 12 weeks of simeprevir (150 mg qd) in combination with sofosbuvir (400 mg qd) in chronic hepatitis C virus (HCV) genotype 1 infected men and women with cirrhosis who are HCV treatment-naïve or treatment-experienced.","primaryOutcome":{"measure":"Percentage of Participants With a Sustained Virologic Response (SVR) 12 Weeks After the Actual End of Treatment (EOT)","timeFrame":"Week 24","effectByArm":[{"arm":"Simeprevir Plus Sofosbuvir","deltaMin":83.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":34,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":103},"commonTop":["Fatigue","Headache","Nausea","Pruritus","Constipation"]}}